Format

Send to

Choose Destination
J Cancer Res Ther. 2018;14(7):1655-1659. doi: 10.4103/jcrt.JCRT_542_18.

Expression of leukocyte immunoglobulin-like receptor B2 in hepatocellular carcinoma and its clinical significance.

Author information

1
Department of Oncology, Jinan Central Hospital, Affiliated to Shandong University, Jinan; Department of Infectious Diseases, Zibo Central Hospital, Zibo, Shandong, China.
2
Department of Oncology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, Shandong, China.
3
Department of Pathology, Zibo Central Hospital, Zibo, Shandong, China.
4
Department of Hepatobiliary and Pancreatic Surgery, Jinan Central Hospital, Affiliated to Shandong University, Jinan, Shandong, China.

Abstract

Background:

Leukocyte immunoglobulin-like receptor B2 (LILRB2) has recently been considered a promising tumor promoter in human cancers.

Materials and Methods:

In this study, the expression of LILRB2 was assessed in 82 samples of surgically resected human hepatocellular carcinoma (HCC) tissues using immunohistochemistry (IHC).

Results:

LILRB2 was overexpressed in HCC tissues and its expression was positively and significantly correlated with poor prognostic features of HCC patients, including poor cell differentiation, larger primary tumor size, and shorter overall survival. In addition, there was a positive correlation between the expression of LILRB2 and its classical ligand human leukocyte antigen G in human HCC tissues.

Conclusion:

LILRB2 might play an important role in HCC progression and correlate with poor prognosis of HCC.

KEYWORDS:

Hepatocellular carcinoma; human leukocyte antigen G; leukocyte immunoglobulin-like receptor B2; prognosis

PMID:
30589055
DOI:
10.4103/jcrt.JCRT_542_18
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center